CYDX (Cyduct Diagnostics) Notes Receivable: $0.00 Mil (As of . 20)


What is Cyduct Diagnostics Notes Receivable?

Cyduct Diagnostics CYDX +4.22% Notes Receivable is $0.00 Mil as of . 20.

Cyduct Diagnostics's Notes Receivable for the quarter that ended in . 20 was $0.00 Mil.

Cyduct Diagnostics Notes Receivable Related Terms

Cyduct Diagnostics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Cyduct Diagnostics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyduct Diagnostics Notes Receivable Chart

Cyduct Diagnostics Annual Data
Trend
Notes Receivable

Cyduct Diagnostics Quarterly Data
Notes Receivable

Cyduct Diagnostics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Cyduct Diagnostics (CYDX) has a Notes Receivable of $0.00 Mil as of . 20. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Cyduct Diagnostics and its competitors.
Is Cyduct Diagnostics' Notes Receivable too high?
Cyduct Diagnostics' current Notes Receivable is $0.00 Mil.
How does Cyduct Diagnostics' Notes Receivable compare to SECI and QTXB?
Cyduct Diagnostics' Notes Receivable of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Cyduct Diagnostics and its competitors. Cyduct Diagnostics's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyduct Diagnostics stock overvalued right now?
Cyduct Diagnostics (CYDX) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Cyduct Diagnostics (CYDX), the current Notes Receivable is $0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cyduct Diagnostics Business Description

Address 1698 Post Road East, Suite 1A, Westport, CT, USA, 06880
Cyduct Diagnostics Inc is a clinical-stage diagnostic company. It focuses on creating and enhancing a portfolio of technologies and assets based on the early assessment and detection of Breast Cancer. Its technology platform of MammoView devices is a single-use, high-margin product that assesses, screens, detects, monitors, and facilitates the treatment of identifiable changes that distinguish variations in breast health. The company markets these products under its Solos Endoscopy brand, along with a line of branded surgical instruments, manufactured by third parties to its design specifications, mainly endoscopes and hand-held surgical instruments for the minimally invasive surgery market.